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SCIENTIFIC OPINION 
Scientific Opinion on the safety and efficacy of Lancer (lanthanide citrate) 
as feed additive for weaned piglets
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Lancer is a feed additive mainly consisting of two rare earth elements, lanthanum (La) and cerium (Ce), in their 
citrate  forms.  In  the  absence  of  an  adequate  tolerance  study  in  weaned  piglets,  the  FEEDAP  Panel  cannot 
conclude  on  the  safety  of  the  additive  for  the  target  species.  Lancer  is  not  genotoxic.  Although  one  study 
suggests that La and Ce are not deposited in tissues in piglets, this is apparently not consistent with data found in 
other species (cattle and rats). Consequently, the Panel is reluctant to conclude that there is no potential for 
consumer exposure. In addition, in the absence of a no observed adverse effect level, the Panel is unable to relate 
any possible exposure to evidence of a safe dose. Lancer is not irritant to skin and eyes and does not induce skin 
sensitisation. The high proportion of particles of diameter less than 10 μm and the high dusting potential suggest 
that the material can be inhaled deep into the lungs of workers. Although the acute respiratory toxicity data 
indicate that the dust is of low toxicity, prolonged/repeated exposure should be avoided. The use of Lancer as a 
feed additive will probably increase the levels of La and Ce above those naturally occurring in the environment. 
Lanthanum  is  potentially  toxic  to  environmental  relevant  species,  but  its  toxicity  is  highly  dependent  on 
speciation. Because of the low solubility of La and Ce, in most situations the additive would probably not give 
rise to concern for the aquatic environment. There are no data on toxicity of the additive to terrestrial organisms. 
In the absence of such data, a full environmental assessment cannot be completed. Based on three studies in 
which  growth  of  piglets  was  positively  affected,  the  Panel  considers  that  Lancer  has  the  potential  to  be 
efficacious. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of the product Lancer when used as a zootechnical feed additive for weaned piglets. Lancer 
consists mainly of two rare earth elements, lanthanum (La) and cerium (Ce), in their citrate forms.  
In the absence of an adequate tolerance study in weaned piglets, the FEEDAP Panel cannot conclude 
on the safety of the additive for the target species. 
Lancer is not genotoxic. Although one study suggests that La and Ce are not deposited in tissues in 
piglets,  this  is  apparently  not  consistent  with  data  found  in  other  species  (cattle  and  rats). 
Consequently, the FEEDAP Panel is reluctant to conclude that there is no potential for consumer 
exposure. In addition, in the absence of a no observed adverse effect level, the Panel is unable to relate 
any possible exposure to evidence of a safe dose.  
Lancer is not irritant to skin and eyes and does not induce skin sensitisation. The high proportion of 
particles of diameter less than 10 μm and the high dusting potential suggest that the material can be 
inhaled deep into the lungs of workers. Although the acute respiratory toxicity data indicate that the 
dust is of low toxicity, prolonged/repeated exposure should be avoided. 
The use of Lancer as a feed additive will probably increase the levels of La and Ce above those 
naturally  occurring  in  the  environment.  Lanthanum  is  potentially  toxic  to  environmental  relevant 
species, but its toxicity is highly dependent on speciation. Because of the low solubility of La and Ce, 
in most situations the additive would probably not give rise to concern for the aquatic environment. 
There are no data on toxicity of the additive to terrestrial organisms. In the absence of such data, a full 
environmental assessment cannot be completed.  
Based  on  the  results  of  three  studies  in  which  growth  of  piglets  was  positively  affected  by  the 
supplementation of Lancer at 250 mg/kg, the FEEDAP Panel considers that Lancer has the potential to 
improve the growth of weaned piglets. Lancer for weaned piglets 
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BACKGROUND  
Regulation  (EC)  No  1831/2003
4  establishes the rules g overning the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The European Commission received a request from Treibacher Industrie AG
5 for authorisation of the 
product  Lancer (lanthanide citrate)  when used as a feed additive for  weaned piglets  (category: 
zootechnical additives; functional group: other zootechnical additives) under the conditions mentioned 
in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under A rticle 4(1) 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the 
applicant  the  technical  dossier  in  support  of  this  application.
6  According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars  and documents submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 11 May 2012. 
The additive  Lancer, a preparation of  lanthanide citrate, has not been previously authorised in the 
European Union. 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Lancer (lanthanide citrate), when used under the conditions described in Table 1. 
                                                       
4   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5   Treibacher Industrie AG. Auer v. Welsbachstrasse 1. 9330 Althofen, Austria. 
6   EFSA Dossier reference: FAD-2011-0050. Lancer for weaned piglets 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive   Lanthanide-citrate (LANCER) 
Registration number/EC 
No/No (if appropriate)   
Category(-ies) of additive  Zootechnical additive 
Functional group(s) of additive  Other zootechnical additives 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Lanthanide citrate  
(RE-citrate, Ln-citrate)  
(IUPAC nomenclature), yellow, 
crystalline powder 
C6H5LnO7 
(Ln = Ce, La) 
At least 65% RE-citrate 
as active substance 
Ln: ICP -SFMS 
Citrate: enzymatical 
 
Trade name (if appropriate)  Lancer 
Name of the holder of 
authorisation (if appropriate)  Treibacher Industrie AG 
 
Conditions of use 
Species or 
category of animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  mg/kg of complete feedingstuffs 
Weaned piglets  Up to 120 
days  250  250  - 
 
Other provisions and additional requirements for the labeling 
Specific conditions or restrictions for 
use (if appropriate)  - 
Specific conditions or restrictions for 
handling (if appropriate)  Avoid inhalation of dust and direct contact with eyes and skin 
Post-market monitoring  
(if appropriate)  - 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
- 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
-  -  -  - Lancer for weaned piglets 
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ASSESSMENT 
1.  Introduction 
The additive Lancer consists of two rare earth elements in their citrate forms, lanthanum (La) and 
cerium (Ce). It is intended to be used as a zootechnical feed additive (other zootechnical additives) in 
weaned piglets. This additive has not previously been authorised in the European Union.  
2.  Characterisation 
2.1.  Characterisation of the additive 
The additive is a dry, yellow, crystalline, odourless powder with a relative density of 2.3 g/cm
3 and 
solubility in water of 85 g/L. According to the specification, the additive consists of 65 % lanthanide 
citrate (La 8.5 ± 0.9 %; Ce 16.3 ± 1.6 %; citrate: 40 ± 5 %). The remainder of the additive consists of 
water (< 10 %), sodium (10 ± 2 %), chloride (10 ± 2 %), other lanthanides (praseodymium (Pr) 2.0 % 
and neodymium (Nd) 0.08 %) and trace elements (< 0.45 %). The analyses of three batches confirmed 
that they met the specification.
7 
The  applicant  provided  the  results  of  analyses  of  three  batches   for  the  following  undesirable 
substances: lead (0.42 mg/kg), cadmium (0.07 mg/kg), mercury (0.21 mg/kg), arsenic (0.50 mg/kg), 
dioxins  and  polychlorinated  biphenyls  ( PCBs)  (0.023–0.035  ng/kg),  mycotoxins  (aflatoxin  B1, 
deoxynivalenol, zearalenone, ochratoxin A), Salmonella (not detected in 10 g), Escherichia coli (not 
detected) and Enterobacteriaceae (<10 CFU/g). All results show compliance with the limits set.
8 
All particles of the product have a diameter smaller than 100 µm,  with approximately 45 % (v/v) 
having a diameter below 10 µm and 10 % having a diameter below 2 µm.
9 Dusting potential measured 
by Heubach dustometer in one batch was 2.6 g/m
3. 
2.2.  Manufacturing process 
The manufacturing process of the product is fully described in the technical dossier. 
2.3.  Stability and homogeneity 
The FEEDAP Panel considers that data on shelf-life are not generally required for mineral-based 
products. However, the applicant provided a single “stress” study in which the product (three batches) 
was stored at 42 °C and 75 % relative humidity for six months. Analysis of La, Ce and citrate showed 
no losses over this period.  
No data were provided on the stability in premixtures and feedingstuffs. However, the concentration of 
the two rare earth elements would not be affected by storage to any measurable extent. 
The capacity of the additive to homogeneously distribute was tested in a piglet feed, in which Lancer 
was supplemented at 250 mg/kg.
10 The analysis of La and Ce content in nine subsamples of the feed 
showed a coefficient of variation of approximately 10 %. 
2.4.  Conditions of use 
Lancer is intended for use in weaned piglets up to 120 days of age at a dose of 250 mg/kg complete 
feedingstuffs, either by direct addition to feed or via a premixture.  
                                                       
7 
 Technical dossier/Section II/Annexes II_12-II_14. 
8 
 Technical dossier/Section II/Annexes II_12-II_14. 
9 
 Technical dossier/Section II/Annex II_5. 
10 
 Technical dossier/Section II/Annex II_11. Lancer for weaned piglets 
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2.5.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substances in animal feed. The Executive Summary of the EURL report can be found in the appendix. 
3.  Safety 
3.1.  Safety for weaned piglets 
3.1.1.  Tolerance  
The  applicant  provided  a tolerance  study  in  piglets  which  is  not  considered  adequate  because  of 
serious flaws in the experimental design and a test material which differed considerably from the 
specifications. Therefore, the FEEDAP Panel cannot conclude on the safety of Lancer for the target 
species. 
3.1.2.  Microbial studies 
A test using the broth dilution method was performed to evaluate the antimicrobial activity of Lancer 
against seven strains of microorganisms (Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 
8739, Salmonella enterica subsp. enterica serovar Abony NCTC 6017, Enterococcus faecium DSM 
20477,  Clostridium  sporogenes  ATCC  19404,  Candida  albicans  ATCC  10231  and  Lactobacillus 
acidophilus ATCC 53103).
11 Positive and negative growth controls were included in the test . In all 
cases, the minimum inhibitory concentration was >200 mg/mL. 
3.2.  Safety for the consumer 
Rare earth elements and their compounds are generally poorly absorbed from the gastrointestinal tract. 
However, some absorption of La, Pr and Ce compounds can occur in bulls (Schwabe et al., 2012), 
where they are mainly distributed to the liver, kidneys and bone. Relatively low levels of residues are 
found in muscle. Similar results were obtained by Ji et al. (1985) in rats. Von Rosenberg et al. (2013) 
did not find any effect on kidney, liver, bone and muscle deposition of La and Ce in pigs after feeding 
Lancer at levels up to 2 500 mg/kg complete feed. 
3.2.1.  Acute toxicity in rats  
Six female Wistar rats were given a single oral gavage dose of Lancer of 2 000 mg/kg body weight 
(bw) and were observed for 14 days.
12 No animals died during the experiment . Transient clinical 
effects included apathy, piloerection, alopecia and kyphosis . Necropsy and microscopic examination 
of tissues showed no treatment-related adverse effects. The results indicate that Lancer is of low acute 
oral toxicity. 
3.2.2.  Genotoxicity  
3.2.2.1.  Bacterial reverse mutation 
Lancer  was  tested  for  mutagenicity  in  a  bacterial  reverse  mutation  assay  (compliant  with  OECD 
Guideline 471) using Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 
in the presence and absence of the S9 microsomal fraction from the livers of male Wistar rats treated 
orally  with  phenobarbital  and  β-naphthoflavone.
13  Two independent experiments were performed 
using the plate incorporation and the pre-incubation methods. Concentrations of up to 5 000 μg/plate 
were used in both experiments. The results of both experiments indicated that the test material is not 
mutagenic. 
                                                       
11 
 Technical dossier/Section III/Annex III_9. 
12 
 Technical dossier/Section III/Annex III_10. 
13 
 Technical dossier/Section III/Annex III_12. Lancer for weaned piglets 
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3.2.2.2.  In vitro mammalian chromosomal aberration test  
Lancer was tested for clastogenicity in an in vitro cytogenetics assay (OECD Guideline 473) using 
Chinese hamster V79 cells in the presence and absence of the S9 microsomal fraction from the livers 
of  male  Wistar  rats  treated  orally  with  phenobarbital  and  β-naphthoflavone.
14  Two independent 
experiments were performed, using Lancer concentrations of up to 5 000 μg/mL in experiment 1 with 
and without S9 and in experiment 2 without S9 and up to 900 µg/mL in experiment 2 with S9. In both 
experiments,  there  were  no  biologically  relevant  increases  in  the  numbers  of  cells  showing 
chromosomal aberrations or polyploidy, indicating that the test material is not clastogenic. 
3.2.2.3.  In vitro mammalian micronucleus assay 
Lancer was tested for clastogenicity in an in vitro micronucleus assay (OECD Guideline 487) using 
Chinese hamster V79 cells in the presence and absence of the S9 microsomal fraction from the livers 
of  male  Wistar  rats  treated  orally  with  phenobarbital  and  β-naphthoflavone.
15  Two independent 
experiments were performed. Experiment 1 used an exposure time of four hours and concentrations of 
test substance of up to 2 500 μg/mL in the presence of S9 and up to 1 500 μg/mL in its absence; 
experiment 2 used an exposure time of 24 hours and concentrations of up to 750 μg/mL in the absence 
of metabolic activation (no S9 was used in experiment 2). There was no treatment-related increase in 
the number of micronucleated cells in either experiment. 
The results of the available mutagenicity studies demonstrated that Lancer is not genotoxic. 
3.2.3.  Repeated-dose 28-day oral toxicity study 
A dose range-finding study was performed using groups of three male and three female Wistar rats 
given Lancer at a dose of 0, 250, 500 or 1 000 mg/kg bw by daily oral gavage for 28 days.
16 At the end 
of the treatment period, all animals were killed  and necropsy performed. No clinical signs of toxicity 
were seen. There were n o treatment-related effects on mortality, food consumption, haematology, 
gross pathology or organ weights   at any dose. Blood biochemistry resul ts showed a dose -related 
increase in mean serum alanine transaminase  activity in males and dose -related increases in mean 
alkaline phosphatase activity in both sexes, although all of the values for individual animals were 
within the normal ranges. No adverse effects were seen at 250 mg/kg bw  per day but the group size 
was too small to allow this to be reliably identified as a no observed adverse effect level (NOAEL). 
3.2.4.  Repeated dose 90-day oral toxicity study  
Groups of 10 male and 10 female Wistar rats were given Lancer at doses of 0, 100, 300 or 600 mg/kg 
bw by daily oral gavage for 90 days.
17 All animals were observed daily for any clinical signs and a 
more detailed examination of each animal was made each week.  Functional observations were made 
prior to treatment and at termination. Body weights and food intake were recorded weekly. At the end 
of the treatment period, all animals were killed  and necropsy performed. Urine and blood samples 
were taken for haematology, blood biochemistry and urinalysis only at the end of the treatment period. 
The animals in the control and the highest dose groups were subjected to extensive histopathological 
examination. In addition, the lungs, mesenteric lymph nodes and stomach of the animals of the other 
groups were examined histopathologically. There were no unscheduled deaths. Some clinical signs of 
toxicity were observed in some of th e males in the  highest dose group. The clinical signs included 
reduced activity, piloerection and nasal discharge. Functional and behavioural observations revealed 
no other abnormalities. Body weight gain was decreased in males in the highest dose group, but feed 
intake was unaffected. The treatment did not affect any of the parameters covered by haematology, 
blood biochemistry or urinalysis. Autopsies showed gross pathological changes in the stomach 
(thickened  mucosa)  and lungs  (dark spots or discoloration )  of some animals, but there were no 
treatment-related effects on weights of any organs. Microscopic examination showed lesions in the 
                                                       
14 
 Technical dossier/Section III/Annex III_13. 
15 
 Technical dossier/Section III/Annex III_14. 
16 
 Technical dossier/Section III/Annex III_15. 
17 
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lungs, forestomach and mesenteric lymph nodes. The lungs showed a combination of intra-alveolar 
eosinophilic material, multifocal granulomatous reaction, multifocal alveolar macrophages,  foci of 
pneumonitis, mineralisation and/or mixed cell perivascular infiltrates with dose-related incidence and 
severity in animals of both sexes from all treated groups. The pathologist’s report noted that these lung 
lesions were “considered to be representative of multifocal subacute bronchopneumonia with foreign 
body reaction, as a direct effect of the test material”. The forestomachs showed epithelial hyperplasia 
of the limiting ridge in both sexes given 300 or 600 mg/kg bw per day and in males given 100 mg/kg 
bw  per  day.  The  mesenteric  lymph  nodes  showed  an  increased  incidence  and  severity  of 
microgranulomas in both sexes at the highest dose level (600 mg/kg bw per day). A NOAEL could not 
be identified for this study as histopathological changes were produced at all dose levels tested. 
3.2.5.  Carcinogenicity 
No carcinogenicity studies were available for Lancer. It is noted that Lancer is not considered to be 
genotoxic and that there appears to be no known carcinogenic hazard associated with rare earth metals. 
However, it is not known whether the forestomach hyperplasia seen in the 90-day rat study would 
have progressed to cancer if the exposure had been more prolonged.  
3.2.6.  Reproduction and developmental toxicity 
No studies of reproductive toxicity or developmental toxicity were available for  Lancer. Negative 
results for the reproductive toxicity testing of related compounds gives limited assurance that Lancer 
may not be a reproductive toxin (Hutcheson et al., 1975; Briner et al., 2000).
18  
In a three-generation reproduction study (Hutcheson et al., 1975), a mixture of 10 metal oxides that 
had been proposed as markers for use in nutritional experiments was tested in CF -1 mice at dietary 
levels that were 1, 10, 100 and 1 000 times the intended use level. The concentrations of metals at the 
intended use level were 0.40 mg/kg La, 0.80 mg/kg samarium (Sm), 0.036 mg/kg europium (Eu), 1.20 
mg/kg terbium (Tb), 1.20 mg/kg dysprosium (Dy), 0.08 mg/kg thulium (Tm), 0.12 mg/kg ytterbium 
(Yb),  0.12 mg/kg  scandium (Sc)  and 0.008  mg/kg  barium  (Ba).  Body  weight gain was slightly 
depressed (compared with untreated controls) at all dose levels in young rats aged three to six weeks, 
but there was no difference in body weights at adulthood. There were no treatment-related effects on 
mortality, general appearance, haematology, reproduction, development of offspring or lactational 
performance. It can be concluded that lanthanum oxide at up to 400  mg/kg in the diet had no adverse 
effects on reproduction other than possibly a small effect on body weight gain. 
A poorly described developmental toxicity test in rats (Ji et al., 1985) showed no malformation of the 
embryos or fetuses of pregnant Wistar rats treated with  rare earth nitrates at 16–2 000 mg/kg bw, but 
the survival of offspring was decreased at 80–400 mg/kg bw (no effect at 2 000 mg/kg bw). 
A  neurodevelopmental  study  (Briner  et  al.,  2000)  was  performed  in  Swiss  Webster  mice  using 
lanthanum chloride (LaCl3·7H2O) at concentrations in drinking water of 0, 125, 250 and 500 mg/L, 
which was administered to the mice prior to conception, throughout gestation and until 30 days post-
natally. Brain weight was significantly lower in the offspring of mice in the highest dose group than in 
the offspring of control mice. Various adverse effects were seen in the offspring of the treated mice, 
including  adverse  effects  on  the  development  of  swimming  and  walking  behaviour,  ear  and  eye 
opening times, touch response and visual placing response, but none of these effects exhibited a dose–
response relationship, and mice treated with lanthanum chloride at all dose levels were affected in 
some  way  or  another.  The  results  of  this  study  showed  some  subtle  effects  on  neurobehavioural 
development that are difficult to interpret. No clear NOAEL was identified. 
3.2.7.  Conclusions on consumer safety 
Lancer is not genotoxic. Although one study suggests that La and Ce are not deposited in tissues in 
piglets,  this  is  apparently  not  consistent  with  data  found  in  other  species  (cattle  and  rats). 
                                                       
18 
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Consequently, the FEEDAP Panel is reluctant to conclude that there is no potential for consumer 
exposure. In addition, in the absence of a NOAEL, the Panel is unable to relate any possible exposure 
to evidence of a safe dose.  
3.3.  Safety for the user 
3.3.1.  Acute inhalation toxicity 
The acute respiratory toxicity of dust generated from Lancer was investigated in Sprague–Dawley 
rats.
19 Five rats of each sex were exposed, nose only, to the dust for four hours. The gravimetric and 
nominal concentrations were 5.06 and 17.54 mg/L   air,  respectively, with the dust  consisting of 
particles with a mass median aerodynamic diameter of 2.45 μm. Following exposure, all animals 
exhibited  clinical  signs  of  toxicity,  including  abnormal  respiration,  hunched  posture,  hypoactivity 
and/or piloerection, but all signs had disappeared by five days post exposure. Four males and two 
females lost body weight in the seven days following treatment, but all animals had gained body 
weight by the end of the study. No gross abnormalities were observed at necropsy. The results indicate 
that the concentration of Lancer that was tested did not have lasting harmful effects.  
3.3.2.  Effects on skin and eyes  
Skin and eye irritation studies were performed in New Zealand White rabbits in accordance with 
OECD Guidelines 404 and 405.
20 Lancer was not irritant to rabbit skin and eyes. 
A local lymph node assay was  performed in mice following a protocol that conformed to OECD 
Guideline 429.
21 Lancer did not produce any sensitisation in any of the mice and , therefore, is not 
regarded as a potential skin sensitiser. 
3.3.3.  Conclusions on user safety 
Lancer is not irritant to skin and eyes and does not induce skin sensitisation. The high proportion of 
particles of diameter less than 10 μm and the high dusting potential suggest that the material can be 
inhaled deep into the lungs of workers. Although the acute respiratory toxicity data indicate that the 
dust is of low toxicity, prolonged/repeated exposure should be avoided. 
3.4.  Safety for the environment 
According to the applicant, the use of Lancer as a feed additive may result in environmental levels of 
La and Ce higher than those naturally occurring. The applicant submitted two studies that showed no 
effects on survival of zebra fish and Daphnia magna following exposure to Lancer at 100 mg/L for 96 
and 24 hours, respectively. However, both studies were conducted in water chemistries in which the 
additive was insoluble. Lanthanum can be toxic to aquatic organisms, presumably because of its high 
potency to block calcium channels (Biagi and Enyeart, 1990; Hogstrand et al., 1996). Its toxicity is 
highly dependent upon water chemistry. For example, Barry and Meehan (2000) reported a 48-hour 
EC50  value  of  lanthanum  for  Daphnia  carniata  as  low  as  43  µg/L  in  soft  water  and  as  high  as 
1 180 μg/L in hard water. Natural conditions in which La would be expected to be toxic (waters with 
low hardness, low alkalinity and low total CO2) cannot be excluded but are probably uncommon 
because of the high propensity of La to form complexes (Cetiner and Xiong, 2008).  
Limited information of relevance for environmental toxicology is available for Ce and none for cerium 
citrate alone. Existing information suggest that Ce salts are poorly soluble in water under realistic 
environmental concentrations. Consequently, the no observed effect concentration >100 mg/L derived 
from CeO2 was probably derived from a study of the slurry rather than of the dissolved metal, and 
consequently may have underestimated toxicity.  
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The additive has not been tested for toxicity to terrestrial organisms. Available data exist only for 
CeO2, which appears to be non-toxic to earthworms and several plant species. Corresponding data for 
La are not available. 
3.4.1.  Conclusions on safety for the environment 
Lanthanum is potentially toxic to environmental relevant species, but its toxicity is highly dependent 
on speciation. Because of the low solubility of La and Ce in most situations, the additive would 
probably not cause a concern for the aquatic environment. There are no data on toxicity of the additive 
to  terrestrial  organisms.  In  the  absence  of  such  data,  a  full  environmental  assessment  cannot  be 
completed.  
4.  Efficacy  
Three efficacy studies were performed, all with a duration of 42 days (study 3, 43 days), in which the 
effect of supplementing Lancer at 250 mg/kg were compared with the effects of a negative control. 
4.1.  Trial 1 
A total of 192 weaned piglets (88 gilts and 104 barrows) were equally distributed into two treatments, 
control and Lancer (250 mg/kg complete feed).
22 All piglets were kept in pens, each litter separately, 
and fed ad libitum. There were eight replicates in both the control and the Lancer-treated groups. Body 
weight  was  measured  at  the  beginning  of  the  experiment  and  body  weight  and  feed intake  were 
measured at days 14, 28, 35 and 42. Data were analysed by a two-way analysis of variance (ANOVA). 
Piglets in the treated group grew faster and were heavier at the end of the trial than those in the control 
group (Table 2). No differences were observed in feed intake, but feed to gain ratio was significantly 
improved by supplementation with Lancer. Seven piglets died or were culled in the control group, 
whereas only three died or were removed from the treated group. 
4.2.  Trial 2  
A  total  of  144  piglets  (68  gilts  and  76  barrows)  were  equally  randomly  distributed  to  the  two 
treatments, control and Lancer (250 mg/kg complete feed).
23 All piglets were kept in pens, each litter 
separately, and fed ad libitum. There were six replicates in the control group and seven replicates in 
the Lancer group. Body weight was measured at the beginning of the experiment and body weight and 
feed intake were measured on days 14, 28, 35 and 42. Data were analysed by a two-way ANOVA. 
Piglets in the treated group grew faster and were heavier at the end of the trial than those in the control 
group (Table 2). No differences were observed in feed intake or feed to gain ratio. Seven animals died 
or were culled in the control group, while only three were culled in the treated group.  
4.3.  Trial 3  
A total of 258 weaned piglets were distributed into two treatments (unsupplemented control group: 60 
males, 71 females; Lancer group: 59 male; 68 female). The study was carried out in five timeshifted 
repetitions. Individual body weight and feed intake per pen were measured on days 7, 21, 35 and 43 
(end of the study). 
The supplementation with Lancer did not significantly influence the final body weight, feed intake and 
the feed to gain ratio, but the overall daily weight gain is reported to be significantly higher in pigs 
supplemented with Lancer (477 vs. 497 g/day; P < 0.05). This result is surprising, because the Lancer 
supplemented  animals  showed  significantly  higher  daily  weight  gains  in  only  one  out  of  five 
repetitions. 
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Table 2:   Summary of the performance parameters of the three studies with weaned piglets 
Trial 
Lancer 
(mg/kg 
feed) 
Initial 
weight 
(kg) 
Final weight 
(kg) 
Feed intake 
(g/day) 
Average 
weight gain 
(g/day) 
Feed/gain  Dead/culled 
(n) 
1 
0  8.0  18.8b  585  258b  2.29a  4/3 
250  7.8  20.1a  562  292a  1.94b  1/2 
2 
0  8.0  19.5b  617  274b  2.23  4/3 
250  8.0  20.7a  596  302a  2.01  –/3 
3 
0  8.8  29.3  782  477b  1.64  –/– 
250  8.7  30.1  788  497a  1.59  –/3 
a,bMeans in a column for a given experiment with different superscript letters are significantly different (P ≤ 0.05). 
4.4.  Conclusions on efficacy 
Based  on  the  results  of  three  studies  in  which  growth  of  piglets  was  positively  affected  by  the 
supplementation of Lancer at 250 mg/kg, the FEEDAP Panel considers that Lancer has the potential to 
improve the growth of weaned piglets. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
24  and  Good 
Manufacturing Practice. 
CONCLUSIONS  
In the absence of an adequate tolerance study in weaned piglets, the FEEDAP Panel cannot conclude 
on the safety of the additive for the target species. 
Lancer is not genotoxic. Although one study suggests that La and Ce are not deposited in tissues in 
piglets,  this  is  apparently  not  consistent  with  data  found  in  other  species  (cattle  and  rats). 
Consequently, the FEEDAP Panel is reluctant to conclude that there is no potential for consumer 
exposure. In addition, in the absence of a NOAEL, the Panel is unable to relate any possible exposure 
to evidence of a safe dose.  
Lancer is not irritant to skin and eyes and does not induce skin sensitisation. The high proportion of 
particles of diameter less than 10 μm and the high dusting potential suggest that the material can be 
inhaled deep into the lungs of workers. Although the acute respiratory toxicity data indicate that the 
dust is of low toxicity, prolonged/repeated exposure should be avoided. 
The use of Lancer as a feed additive will probably increase the levels of La and Ce above those 
naturally  occurring  in  the  environment.  Lanthanum  is  potentially  toxic  to  environmental  relevant 
species, but its toxicity is highly dependant on speciation. Because of the low solubility of La and Ce, 
in most situations the additive would probably not cause a concern for the aquatic environment. There 
are no data on toxicity of the additive to terrestrial organisms. In the absence of such data, a full 
environmental assessment cannot be completed. 
Based  on  the  results  of  three  studies  in  which  growth  of  piglets  was  positively  affected  by  the 
supplementation with Lancer at 250 mg/kg complete feed, the FEEDAP Panel considers that Lancer 
has the potential to improve the growth of weaned piglets. 
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APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for Lancer (lanthanide citrate)
25 
In  the  current  application  authorisation  is  sought  under  article  4(1)  for  lanthanide  citrate  under 
category/functional group 4(d) "zootechnical additives"/"other zootechnical additives", according to 
the classification system of Annex I of Regulation (EC) No 1831/2003. 
Authorisation  is  sought  for  the  use  of  the  feed  additive  for  weaned  piglets.  Lanthanide  citrate 
(Lancer
®) is a yellow crystalline powder consisting mainly of lanthanum and cerium citrates with a 
minimum purity of 65 % lanthanide citrate. The feed additive is intended to be incorporated through 
premixtures or directly in feedingstuffs to achieve a content of 250 mg Lancer®/kg feedingstuffs, which 
corresponds to 21 mg added lanthanum /kg feedingstuffs and 41 mg added cerium /kg feedingstuffs. 
For the determination of citrate in the feed additive, the Applicant provided no experimental data or 
any analytical methods. However the EURL identified and recommends the European Pharmacopeia 
Monographs  0400  and  0412,  based  on  acid/base  titration  with  0.1  M  perchloric  acid  and 
naphtholbenzein as indicator, for the quantification of citrate in the feed additive. 
The direct quantification of the rare-earth citrates (Lancer
®) in premixtures and feedingstuffs is not 
experimentally  achievable.  The  Applicant  submitted  instead  a  single-laboratory  validated  multi-
analyte method based on Inductively Coupled-Mass Spectrometry (ICP-MS) for the quantification of 
the total lanthanum and cerium in the feed additive and in feedingstuffs. Premixtures samples can be 
diluted in blank feed and analysed as feed samples.  
Based on the performance characteristics presented and the experimental evidence available the EURL 
recommends for official control the single-laboratory validated ICP-MS method applying the sample 
preparation  protocol  described  in  the  CEN  standards  (EN  15510  or  CEN/TS  15621)  for  the 
quantification of total lanthanum and total cerium in the feed additive, premixtures and feedingstuffs. 
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 
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